Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.65% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M 100.0% | $9.5M 100.0% | $8.9M 100.0% | $14.7M 100.0% | $4.3M 100.0% | $1.8M 100.0% | $3.5M 100.0% | $5.0M 100.0% | $3.5M 100.0% | $5.9M 100.0% |
| Cost of Revenue | — | $334K 3.5% | $671K 7.5% | $728K 5.0% | $1.4M 32.8% | $385K 21.1% | $412K 11.7% | $302K 6.1% | $168K 4.9% | $358K 6.0% |
| Gross Profit | — | — | $8.3M 92.5% | $14.0M 95.0% | $2.9M 67.2% | $1.4M 78.9% | $3.1M 88.3% | $4.7M 93.9% | $3.3M 95.1% | $5.6M 94.0% |
| Research & Development | $17.7M 121.8% | $12.5M 131.3% | $15.7M 175.6% | $14.0M 95.1% | $33.9M 781.2% | $12.3M 674.5% | $17.9M 510.6% | $21.0M 420.1% | $24.0M 694.7% | $36.1M 609.6% |
| Selling, General & Admin | $18.5M 126.8% | $18.2M 191.3% | $17.3M 193.4% | $22.5M 153.1% | $18.2M 419.5% | $15.6M 852.7% | $24.0M 683.7% | $24.7M 495.7% | $19.9M 576.1% | $28.4M 479.9% |
| Total Operating Expenses | $51.2M 351.6% | $31.0M 326.1% | $33.0M 369.0% | $36.5M 248.2% | $52.1M 1200.8% | $27.9M 1527.3% | $42.0M 1194.3% | $46.5M 931.9% | $43.9M 1270.9% | $64.5M 1089.5% |
| Operating Income | -$36.6M -251.6% | -$21.5M -226.1% | -$24.7M -276.5% | -$22.5M -153.2% | -$49.2M -1133.6% | -$26.4M -1448.4% | -$38.9M -1106.0% | -$41.8M -837.9% | -$38.9M -1125.0% | -$59.0M -995.6% |
| Interest & Investment Income | — | — | — | — | — | $1.0M 56.9% | $1.7M 47.9% | — | — | — |
| Other Income (Expense), net | -$32.0M -220.0% | $2.9M 30.5% | $1.5M 16.2% | -$3.3M -22.4% | $5.9M 136.9% | $4.5M 247.7% | $19.6M 558.8% | -$5.3M -107.0% | $15.6M 451.5% | $77.6M 1309.9% |
| Pretax Income | -$68.6M -471.6% | -$18.6M -195.6% | -$23.3M -260.3% | -$25.8M -175.6% | -$43.3M -996.8% | -$21.9M -1200.7% | -$19.2M -547.2% | -$47.1M -944.9% | -$23.3M -673.5% | $18.6M 314.4% |
| Income Tax Expense | -$5.3M -36.3% | $0 0.0% | -$1.8M -20.2% | $541K 3.7% | — | -$1.2M -67.9% | -$7.4M -210.7% | $346K 6.9% | — | — |
| Net Income | -$63.5M -436.5% | -$18.6M -195.9% | -$21.5M -240.2% | -$26.3M -178.7% | -$43.0M -991.0% | -$20.6M -1130.8% | -$11.7M -333.1% | -$46.0M -922.0% | -$20.0M -577.7% | $33.6M 566.8% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | — | — | — | $-0.17 | $0.35 |
| EPS (Diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | — | — | — | — | $-0.17 | $0.34 |
| Weighted Avg Shares (Basic) | 230.1M | 200.2M | 172.7M | 169.8M | 164.5M | — | — | — | 114.5M | 97.3M |
| Weighted Avg Shares (Diluted) | 230.1M | 200.2M | 172.7M | 169.8M | — | — | — | — | 114.5M | 99.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$19M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -143%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-05
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 39th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.3× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 6.1 | 11.7 | 21.1 | 32.8 | 5.0 | 7.5 | 3.5 | — |
| Gross Profit | 93.9 | 88.3 | 78.9 | 67.2 | 95.0 | 92.5 | — | — |
| R&D | 420.1 | 510.6 | 674.5 | 781.2 | 95.1 | 175.6 | 131.3 | 121.8 |
| SG&A | 495.7 | 683.7 | 852.7 | 419.5 | 153.1 | 193.4 | 191.3 | 126.8 |
| Operating Income | -837.9 | -1106.0 | -1448.4 | -1133.6 | -153.2 | -276.5 | -226.1 | -251.6 |
| Income Tax | 6.9 | -210.7 | -67.9 | — | 3.7 | -20.2 | 0.0 | -36.3 |
| Net Income | -922.0 | -333.1 | -1130.8 | -991.0 | -178.7 | -240.2 | -195.9 | -436.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on LCTX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| LCTX | $277M | — | — | 19.0× | 53.2% | — | -436% | -143% | -143% | — | 127 |
Peers = companies sharing LCTX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.